Post-earnings recap
Reported
Wed, May 1, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a strong EPS performance, exceeding expectations by nearly 16%. The stock reacted positively, rising nearly 4% in response to the earnings report. However, the lack of revenue figures and forward guidance leaves some uncertainty about the company's overall performance and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.20 | N/A | +15.94% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. They emphasized the importance of ongoing projects but did not provide specific guidance for the future.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline and delivering value.